Clinical reference Biomarker Directory
Back to directory

HBA1

Emerging

HBA1 is one of the duplicated alpha-globin genes; its deletion causes alpha-thalassemia of variable severity.

Also known as Alpha-globin gene 1
In plain language

HBA1 is one of the genes that makes part of hemoglobin. When copies of this gene are missing, it causes alpha-thalassemia, ranging from harmless to life-threatening depending on how many copies are affected. Genetic testing helps identify carriers before they have children.

Biomarker & context

HBA1 is one of two duplicated alpha-globin genes (with HBA2); deletions or mutations affecting these genes cause alpha-thalassemia, a common inherited blood disorder.

What it indicates

Genetic testing of HBA1/HBA2 confirms alpha-thalassemia, ranging in severity from silent carrier states (one gene deleted) to Hemoglobin H disease (three genes deleted) to the fatal Hb Bart's hydrops fetalis (all four alpha genes deleted).

Diagnosis & clinical testing

Diagnosed via hemoglobin electrophoresis or HPLC as an initial step, with HBA1/HBA2 gene testing (often via multiplex PCR or gap-PCR to detect deletions) providing definitive genetic confirmation, especially important for carrier screening and prenatal counseling.

Guiding treatment

Genetic testing is standard in thalassemia carrier screening, especially in at-risk ethnic populations (Southeast Asian, Mediterranean, African, Middle Eastern ancestry), informing reproductive planning given the risk of severe disease in offspring of two carrier parents.

Clinical significance

Genetic testing is standard for carrier screening in at-risk populations, given risk of severe disease in offspring of two carriers.

References
  1. General hematology/genetics reference literature on alpha-thalassemia genetics and carrier screening.